To ensure a successful drug launch, biotech companies must start their commercialization planning at least 18 months in advance. This lead time is essential for deeply understanding the patient journey, identifying treatment barriers, and aligning clinical trials with outcomes that truly matter to patients and payers.

The first commercial priority for a clinical-stage biotech should be payer and health economics (HEOR) research. This ensures the clinical trial includes endpoints that demonstrate clear value to payers, which is essential for future reimbursement and market access.

Rather than waiting for late-stage development, biotech startups should integrate commercial planning into early trials. This means building in data collection for payers, pricing, and patient access from the start. This "think with the end in mind" approach ensures the company has the right data for pivotal trials and market access.

Iolyx CEO Elizabeth Jeffords insists on commercial input even in preclinical stages. This meant killing an ointment formulation—which patients find 'greasy' and 'disgusting'—in favor of developing a more patient-friendly eyedrop. This avoids creating a product that is clinically sound but has poor real-world adoption.

CervoMed hired its Chief Commercial Officer before starting Phase III to ensure the trial design supports future commercialization. This avoids the common mistake of treating market access as an afterthought to be "bolted on" after receiving positive data.

For a successful drug launch, biotech companies must abandon a sequential, siloed approach. The key is to start early, using an agile model where all functions (medical, commercial, regulatory) work in an integrated way from the outset. Rushing this complex process leads to costly mistakes.

Many biotechs focus R&D solely on regulatory approval. Beren Therapeutics integrates commercial thinking early to ensure clinical development answers a different question: Is what we're building meaningful to patients, payers, and providers? This de-risks the asset for commercial success, not just clinical milestones.

Biotech leaders must stop viewing commercialization as a post-approval task. The critical window is Phase 2 clinical trials. By embedding patient journey and quality of life insights into secondary endpoints, companies can build a compelling value proposition for payers and physicians. Waiting until Phase 3 is too late.

Acadia's R&D process starts by considering what will ultimately matter to patients, physicians, and payers. This "end in mind" approach ensures clinical trials are designed to demonstrate meaningful, commercially relevant benefits. It forces realism about a drug's potential impact early in development, avoiding wasted resources on therapies that won't be adopted.